OHDSI Home | Forums | Wiki | Github

Phenotype Submission - Warm Autoimmune Hemolytic Anemia (wAIHA)

Cohort Definition Name : Earliest event of Warm Autoimmune Hemolytic Anemia (wAIHA), occurring on or after October 2020
Contributor name : ‘Jill Hardin’
Contributor OrcId :
Logic Description : Earliest occurrence of Warm Autoimmune Hemolytic Anemia (wAIHA) indexed on diagnosis date, for the first time in history occurring on or after October 2020 cohort exit is the end of continuous observation
Recommended study application : target
Assertion statement : This cohort definition was executed on at least one real person-level observational health data source and resulted in a cohort with at least 1 person.
Target Clinical Description : Autoimmune hemolytic anemia (AIHA) is a rare acquired autoimmune disease in which autoantibodies lead to accelerated destruction of red blood cells. “Warm” autoimmune hemolytic anemia (wAIHA) is red cell destruction occurring in the presence of warm agglutinins that bind at temperatures of 37°C, and accounts for between 60-80% of AIHA. wAIHA is a chronic, relapsing disease that confers an elevated risk of venous thrombolic events and mortality. Median age of onset is 50-60 years old and tends to more commonly affect females. An estimated half of cases are idiopathic, with the other half being secondary to other disorders, typically autoimmune or lymphoproliferative, or medications.
Evaluation conclusion : We developed one prevalent cohort definition for warm antibody autoimmune hemolytic anemia (wAIHA) using concept sets which incorporated all those found from the literature review and from the analysis of PHOEBE and orphan concepts in cohort diagnostics. We developed a prevalent cohort definition for Polyarticular Juvenile Idiopathic Arthritis (PJIA) using a concept set of 6 concepts which incorporated all those found from the literature review, the analysis of PHOEBE, and orphan concepts in cohort diagnostics as well as after consultation with a rheumatologist. We performed the evaluation across a network of claim data sources and 1 EHR US data source. The data sources are:
IBM® MarketScan® Commercial Database (CCAE), Optum’s longitudinal EHR repository (Optum EHR), Optum’s Clinformatics® Data Mart (DOD), IBM® MarketScan® Multi-State Medicaid Database (MDCD), IBM® MarketScan® Medicare Supplemental Database (MDCR), Japan Claims Database (JMDC), Clinical Practice Research Datalink (CPRD) , IQVIA® Australia Longitudinal Patient Data (LPD) database (Australia), IQVIA® Disease Analyzer (DA) France database (France), QVIA® Disease Analyzer (DA) Germany database (Germany), IQVIA® Adjudicated Health Plan Claims Data (formerly PharMetrics Plus) - US database (PharMetrics), IQVIA® Ambulatory EMR (EMR). The algorithm retrieves subjects from 6 out of the 11 databases tested. We found there was no need to correct for index date misclassification. Further the code used to identify subjects for this phenotype was introduced in October 2020 and use of alternative codes to identify subjects prior to that time results in misspecification of subjects. Due to the limited number of subjects in this phenotype use of the Phevaluator tool was not possible hence there are no metrics to quantify the phenotype performance.

Imported to the OHDSI Phenotype Library. It may be expected to be found with id = 1018 in the next release. Thank you